Showing 7951-7960 of 8629 results for "".
- Modernizing Medicine Introduces Practice Management Solutionhttps://practicaldermatology.com/news/modernizing-medicine-introduces-practice-management-solution/2458792/Modernizing Medicine, Inc., creator of the Electronic Medical Assistant® (EMA™), introduced its new practice management solution, modmed PM, at the company’s second annual EMA Nation Users Conference. Building on the success Modernizing Medicine has achieved by employing s
- Aqua Pharmaceuticals Acquires US Rights to Veltin Gel and Altabax Ointmenthttps://practicaldermatology.com/news/aqua-pharmaceuticals-acquires-us-rights-to-veltin-gel-and-altabax-ointment/2458795/Aqua Pharmaceuticals, LLC acquired the US rights to two dermatology products— Veltin (clindamycin phosphate and tretinoin) Gel 1.2%/0.025% and Altabax (retapamulin) Ointment 1%, after Almirall, parent company of Aqua, acquired the rights to the products from GlaxoSmithKline. Both Veltin and
- Data: Acne Sufferers Lack Understanding About Use of Antibiotics to Treat Acne and Potential Resistancehttps://practicaldermatology.com/news/data-acne-sufferers-lack-understanding-about-use-of-antibiotics-to-treat-acne-and-potential-resistance/2458797/A recent survey sponsored by Galderma Laboratories, L.P., inclusive of 809 acne sufferers (ages 17-40 years) and 210 parents of acne sufferers (child, aged 9-17 years), found that despite the risk of antibiotic resistance and potential side effects:
- DermTech Announces New Websitehttps://practicaldermatology.com/news/dermtech-announces-new-website/2458796/DermTech, Inc., a privately held commercial stage molecular diagnostic company developing gene expression tests for skin cancer, announced the release of its new website (www.dermtech.com), designed to provide education and inf
- Asian Acne Board and Galderma Join Forces to Improve Understanding and Management of Acnehttps://practicaldermatology.com/news/asian-acne-board-and-galderma-join-forces-to-improve-understanding-and-management-of-acne/2458799/The Asian Acne Board (AAB) and Galderma are inviting candidates to apply for a research grant of $10,000 to contribute to the improvement of best practices in the management of acne. The AAB research grant with the unrestricted support of Galderma is focused on advancing the understa
- Study Finds Increasing Prices for Prescription Dermatology Drugs Since 2009https://practicaldermatology.com/news/study-finds-increasing-prices-for-prescription-dermatology-drugs-since-2009/2458800/A recent study published in JAMA Dermatology found that the price of prescription dermatologic drugs rose considerably from 2009 to 2015, with the vast majority of price increases occurring after 2011. In an effo
- Novartis receives FDA regular approval for Tafinlar + Mekinist for Melanomahttps://practicaldermatology.com/news/novartis-receives-fda-regular-approval-for-tafinlar-mekinist-for-melanoma/2458804/The FDA granted regular approval for the combination of Tafinlar® (dabrafenib) + Mekinist® (trametinib) from Novartis for the treatment of patients with BRAF V600E/K mutation-positive unresectable or metastatic melanoma as detected by an FDA-approved test. This is th
- Data Show Acne Patients Don't Understand Risks Associated with Antibiotic Treatmenthttps://practicaldermatology.com/news/data-show-acne-patients-dont-understand-risks-associated-with-antibiotic-treatment/2458805/Widespread and inappropriate use of antibiotics continues to be a problems in the US leading to antibiotic resistance issues. While most people understand how the overuse of antibiotics to treat viral infections contributes to this issue, according to Galderma, new data reveal that acne patients
- ASDSA Patient Safety Hero Honorees Recognizedhttps://practicaldermatology.com/news/asdsa-patient-safety-hero-honorees-recognized/2458810/The American Society for Dermatologic Surgery Association (ASDS) announced its Patient Safety Hero Award recipients during the recent 2015 ASDS Annual Meeting in Chicago to recognize leaders who have taken an active role in the promotion and protection of patient safety in dermatologic procedures
- Ortek Therapeutics Files Patent Applications for New Microbiome to Reduce S. Aureus Proliferationhttps://practicaldermatology.com/news/ortek-therapeutics-files-patent-applications-for-new-microbiome-to-reduce-s-aureus-proliferation/2458808/Stony Brook University and Ortek Therapeutics, Inc. filed two patent applications in the United States and internationally for nutrient based compositions utilizing innovative microbiome technology. Developed at Stony Brook University, these compositions have been exclusively licensed to Ortek as